R

ise and shine, folks, another busy day is on the way. Despite the mounting workload, this morning is getting off to a reasonably good start, thanks to a warm and shiny sun enveloping the Pharmalot campus. Moreover, our short people have successfully departed for their respective destinations and the official mascots have quietly settled down. All of which means the time has come to get cracking. On that note, here are some items of interest. We hope your day is productive and do keep in touch …

GlaxoSmithKline (GSK) agreed to pay Novartis (NVS) $13 billion for its 36.5 percent stake in their consumer health care joint venture, moving to consolidate the unit just three years after GSK and Novartis teamed up, the Wall Street Journal reports. The deal is the first significant strategic move for the newly installed executives running both companies and follows transactions a few years ago between the drug makers in which Glaxo beefed up consumer health and vaccines, while Novartis bought the Glaxo cancer drugs business.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.